Альтернативи пошуку:
justifications » justification (Розширити пошук)
purification » verification (Розширити пошук), clarification (Розширити пошук), publication (Розширити пошук)
codification » notification (Розширити пошук), clarification (Розширити пошук), certification (Розширити пошук)
justifications » justification (Розширити пошук)
purification » verification (Розширити пошук), clarification (Розширити пошук), publication (Розширити пошук)
codification » notification (Розширити пошук), clarification (Розширити пошук), certification (Розширити пошук)
-
41
Supplementary Table S2 from A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
Опубліковано 2025Предмети: -
42
Taming the Piers–Rubinsztajn Reaction: Beyond B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>
Опубліковано 2025Предмети: -
43
-
44
-
45
المشهور المبني على الضعيف عند المالكية: دراسة تأصيلية - تطبيقية
Опубліковано 2023Отримати повний текст
article -
46
طبيعة التزام طبيب التجميل في قانون المسؤولية الطبية الأردني رقم 25 لسنة 2018
Опубліковано 2024Отримати повний текст
article -
47
Biochemical investigation of wild-type and processed RNG2.
Опубліковано 2025“...<b>(D)</b> Size-exclusion chromatography (SEC) chromatogram of the affinity-purified RNG2-ΔN+CTer variant obtained via Strep-tactin purification. A Coomassie-stained gel of the protein-containing fractions of the SEC is shown on the right. ...”
-
48
-
49
Identification of TesA as the periplasmic partner of YbbAP.
Опубліковано 2025“...<b>(D)</b> SDS-PAGE gel showing co-purification of YbbAP-TesA as a complex. Underlying data can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003427#pbio.3003427.s018" target="_blank">S1 Data</a>–<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003427#pbio.3003427.s020" target="_blank">S3 Data</a>....”
-
50
تشدُّد النقاد في جرح الرواة (مفهومه وأسبابه وضوابطه وآثاره)
Опубліковано 2020Отримати повний текст
article -
51
Factors and outcomes associated with acute kidney injury in brain tumor resection patients: insights from a large US database (2010–2019)
Опубліковано 2025“...We analyzed brain tumor resection admissions from the United States’ National Inpatient Sample database (2010–2019), identifying hospitalizations with and without AKI using International Classification of Diseases, Ninth Revision, Clinical Modification and International Classification of Diseases, Tenth Revision, Clinical Modification codes. ...”
-
52
Table 1_GLP-1 agonists and exercise: the future of lifestyle prioritization.docx
Опубліковано 2025“...<p>Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification. However, long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss. ...”
-
53
Supplementary Material for: Long-Term Remission of Peritoneal Lymphangiomatosis with Sirolimus Therapy: A Case Report with 8-Year Follow-Up
Опубліковано 2025“...After failed conservative management including dietary modification, diuretic therapy, and repeated paracenteses, she was started on sirolimus 2 mg/day in August 2016. ...”
-
54
Generating IAA-regulatable strains of candidate CIA pathway proteins in <i>Toxoplasma gondii.</i>
Опубліковано 2025“...The PCR screens testing for genetic modifications are shown at the bottom of each panel. ...”
-
55
Epitope tagging of candidate CIA pathway proteins in <i>Toxoplasma gondii.</i>
Опубліковано 2025“...The PCR screens testing for genetic modifications are shown at the bottom of each panel. ...”
-
56
-
57
Image 2_Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders.tif
Опубліковано 2025“...Overall, 7.5% of patients carried CYP2D6 variants and 20.6% carried CYP2C19 variants, for which CPIC guidelines recommend alternative drug selection or dose modification.</p>Discussion<p>This study demonstrates a high prevalence of actionable CYP2D6 and CYP2C19 variants in the Central Indian population, underscoring the need for pharmacogenetic integration in psychiatric prescribing in Indian clinical settings, to enhance treatment efficacy and minimize adverse events....”
-
58
Data Sheet 1_Characterization of Ty21a immunostimulatory effects in the mouse bladder.pdf
Опубліковано 2025“...Here, we show that increased immune-cell infiltration was neither associated with modification in blood vessel density nor the generation of high endothelial venules, but rather with a transient increase in local vessel permeability, requiring live bacteria. ...”
-
59
Image 1_Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders.tif
Опубліковано 2025“...Overall, 7.5% of patients carried CYP2D6 variants and 20.6% carried CYP2C19 variants, for which CPIC guidelines recommend alternative drug selection or dose modification.</p>Discussion<p>This study demonstrates a high prevalence of actionable CYP2D6 and CYP2C19 variants in the Central Indian population, underscoring the need for pharmacogenetic integration in psychiatric prescribing in Indian clinical settings, to enhance treatment efficacy and minimize adverse events....”
-
60
Data Sheet 1_Pharmacogenetic variations and clinical implications of actionable CYP2D6/CYP2C19 variants in Central Indian patients with common mental disorders.pdf
Опубліковано 2025“...Overall, 7.5% of patients carried CYP2D6 variants and 20.6% carried CYP2C19 variants, for which CPIC guidelines recommend alternative drug selection or dose modification.</p>Discussion<p>This study demonstrates a high prevalence of actionable CYP2D6 and CYP2C19 variants in the Central Indian population, underscoring the need for pharmacogenetic integration in psychiatric prescribing in Indian clinical settings, to enhance treatment efficacy and minimize adverse events....”